WP's experience at big pharma and rolling out billion dollar drugs gives me a lot reassurance we're heading in the right direction.
Only disappointment is the slow EFS recruitment. May start, we're now in September. That's a big delay for a very small study. Hope these delays don't carry over into the pivotal study.
Eureka report, page-10
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.20 |
Change
-0.550(5.12%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $10.73 | $10.73 | $10.15 | $109.7K | 10.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 490 | $10.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.20 | 911 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |